Literature DB >> 25367856

MR imaging in hepatocellular carcinoma: correlations between MRI features and molecular marker VEGF.

Zhaoqin Huang1, Xiangjiao Meng, Jianjun Xiu, Xiuqin Xu, Lei Bi, Jie Zhang, Xue Han, Qingwei Liu.   

Abstract

The aim of this paper was to investigate the correlations between magnetic resonance imaging (MRI) features and vascular endothelial growth factor (VEGF) in hepatocellular carcinoma (HCC). Thirty-six patients with HCC included in this study underwent dynamic contrast-enhanced MR imaging and diffusion-weighted MR imaging. Signal intensity characteristics of HCCs were reviewed independently by two experienced radiologists. ADC maps were automatically computed. VEGF expression was evaluated by immunohistochemical staining. The grades of the VEGF expression were correlated inversely with the ADC values of the HCCs (r = -0.435, p = 0.008). Intensity heterogeneity correlated with VEGF expression (r = 0.571, p = 0.039). There is a significant correlation between the intensity of arterial enhancement and VEGF expression (r = -0.386, p = 0.02). However, no correlation was found between the VEGF grades and the intensity of enhancement in the hepatic portal venous and late phases, as well as equilibrium phase. Our results indicate that ADC value on DW-MRI, the signal intensity in arterial phase and intensity heterogeneity correlate with the degree of VEGF expression in hepatocellular carcinomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25367856     DOI: 10.1007/s12032-014-0313-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

Review 1.  Epidemiology and management of hepatocellular carcinoma.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Infect Dis Clin North Am       Date:  2010-12       Impact factor: 5.982

2.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

3.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation.

Authors:  D Mukhopadhyay; L Tsiokas; X M Zhou; D Foster; J S Brugge; V P Sukhatme
Journal:  Nature       Date:  1995-06-15       Impact factor: 49.962

4.  Apparent diffusion coefficient value of diffusion-weighted imaging for hepatocellular carcinoma: correlation with the histologic differentiation and the expression of vascular endothelial growth factor.

Authors:  Suk Hee Heo; Yong Yeon Jeong; Sang Soo Shin; Jin Woong Kim; Hyo Soon Lim; Jae Hyuk Lee; Yang Seok Koh; Chol Kyoon Cho; Heoung Keun Kang
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

5.  Expression of vascular endothelial growth factor in human hepatocellular carcinoma.

Authors:  R Yamaguchi; H Yano; A Iemura; S Ogasawara; M Haramaki; M Kojiro
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

Review 6.  Diffusion-weighted MRI in the body: applications and challenges in oncology.

Authors:  Dow-Mu Koh; David J Collins
Journal:  AJR Am J Roentgenol       Date:  2007-06       Impact factor: 3.959

Review 7.  Novel advancements in the management of hepatocellular carcinoma in 2008.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  J Hepatol       Date:  2008-02-12       Impact factor: 25.083

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Authors:  M O Leach; K M Brindle; J L Evelhoch; J R Griffiths; M R Horsman; A Jackson; G C Jayson; I R Judson; M V Knopp; R J Maxwell; D McIntyre; A R Padhani; P Price; R Rathbone; G J Rustin; P S Tofts; G M Tozer; W Vennart; J C Waterton; S R Williams; P Workman
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

10.  Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions.

Authors:  Paola Rita Brunocilla; Franco Brunello; Patrizia Carucci; Silvia Gaia; Emanuela Rolle; Alessandro Cantamessa; Anna Castiglione; Giovannino Ciccone; Mario Rizzetto
Journal:  Med Oncol       Date:  2012-12-22       Impact factor: 3.738

View more
  2 in total

1.  Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation.

Authors:  Zhi Dong; Kun Huang; Bing Liao; Huasong Cai; Yu Dong; Mengqi Huang; Xiaoqi Zhou; Yingmei Jia; Ling Xu; Yanji Luo; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2018-12-13       Impact factor: 5.315

Review 2.  Hepatocellular Carcinoma and Diffusion-Weighted MRI: Detection and Evaluation of Treatment Response.

Authors:  Jill S Gluskin; Fabrizio Chegai; Serena Monti; Ettore Squillaci; Lorenzo Mannelli
Journal:  J Cancer       Date:  2016-07-13       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.